Overview

To Evaluate the Efficacy and Safety of QL1206 and Xgeva in Patients With Bone Metastases From Solid Tumors

Status:
Recruiting
Trial end date:
2022-06-10
Target enrollment:
Participant gender:
Summary
A multi-center, randomized, double-blind, comparative study to evaluate the clinical efficacy and safety of QL1206 and Xgeva® in patients with bone metastases from solid tumors.
Phase:
Phase 3
Details
Lead Sponsor:
Qilu Pharmaceutical Co., Ltd.
Treatments:
Denosumab